Progression on osimertinib: When is it possible to continue with a targeted therapy?

Date 13 April 2018
Event ELCC 2018 European Lung Cancer Congress
Session Guiding the best targeted treatment
Topics Lung and other Thoracic Tumours
Personalised Medicine
Presenter David Planchard
Authors D. Planchard
  • Institut Gustave Roussy, 94800 - Villejuif/FR